An observational study in Hepatitis, Hepatitis B and Lymphoma, sponsored by Peking University. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-24.
Sponsored by Peking University · Observational
This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.
All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's enrollment of 107 is below the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →Peking University is the lead sponsor of 411 studies on the registry; 122 are open to participants now.
Counted across the registry records on this site, refreshed daily.
lymphoma patients with hepatitis B virus infection diagnosed in Peking University Cancer Hospita
Exclusion Criteria:
group with hepatitis B virus reactivation
group without hepatitis B virus reactivation
the incidence of hepatitis B virus delayed reactivation
hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy
Time frame: within one year after withdrawal of prophylactic antiviral therapy
the incidence of hepatitis B virus related hepatitis flare
the incidence of hepatitis B virus related hepatitis flare after withdrawal of prophylactic antiviral therapy
Time frame: within one year after withdrawal of prophylactic antiviral therapy
Number of patients that achieve a tumor response
Time frame: within one year after withdrawal of prophylactic antiviral therapy
overall survival rate
Time frame: within one year after withdrawal of prophylactic antiviral therapy
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University